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Available online 19 March 2016Currently, no therapeutic options exist for castration-resistant prostate cancer (CRPC) patients who have devel-
oped resistance to the second generation anti-androgen receptor (AR) axis therapy. Here we report that co-
deletion of Pten and p53 in murine prostate epithelium, often observed in human CRPC, leads to AR-
independent CRPC and thus confers de novo resistance to second generation androgen deprivation therapy
(ADT) in multiple independent yet complementary preclinical mouse models. In contrast, mechanism-driven
co-targeting hexokinase 2 (HK2)-mediated Warburg effect with 2-deoxyglucose (2-DG) and ULK1-dependent
autophagy with chloroquine (CQ) selectively kills cancer cells through intrinsic apoptosis to cause tumor regres-
sion in xenograft, leads to a near-complete tumor suppression and remarkably extends survival in Pten−/p53-
deﬁciency-driven CRPC mouse model. Mechanistically, 2-DG causes AMPK phosphorylation, which in turn in-
hibits mTORC1-S6K1 translation signaling to preferentially block anti-apoptotic protein MCL-l synthesis to
primemitochondria-dependent apoptosiswhile simultaneously activatesULK1-driven autophagy for cell surviv-
al to counteract the apoptotic action of anti-Warburg effect. Accordingly, inhibition of autophagy with CQ sensi-
tizes cancer cells to apoptosis upon2-DG challenge.Given that 2-DG is recommended for phase II clinical trials for
prostate cancer and CQ has been clinically used as an anti-malaria drug for many decades, the preclinical results
from our proof-of-principle studies in vivo are imminently translatable to clinical trials to evaluate the therapeu-
tic efﬁcacy by the combination modality for a subset of currently incurable CRPC harboring PTEN and TP53
mutations.














Genetically-engineered mouse model1. Introduction
Prostate cancer strikes one in six men and is the second leading cause
of cancer-related deaths in men after lung cancer in the United States.
Prostate cancer arises mainly from prostatic intraepithelial neoplasia
(PIN), a precursor lesion that ultimately progresses to adenocarcinoma
and systemic metastasis (DeMarzo et al., 2003). Conventional androgen
deprivation therapy (ADT) by surgical and/or chemical castration remains
the standard of care for metastatic prostate cancer. Unfortunately, these
prostate cancers invariably develop resistance to ADT and progress to a
more aggressive castration-resistant prostate cancer (CRPC) within 18–
24months. Chemotherapywith docetaxel (Petrylak et al., 2004) or its de-
rivative carbazitaxel after development of docetaxel resistance (de BonoHormel Institute, 801 16th Ave
. This is an open access article underet al., 2010) offers a 3–4 months survival beneﬁt for CRPC patients. The
discovery that persistent androgen receptor (AR) signaling plays a crucial
role in the progression of CRPC leads to “second generation” ADT
modalities (Chen et al., 2004; Tran et al., 2009), such as the Food and
Drug Administration-approved androgen synthesis blocker abiraterone
(2011, FDA) and the second generation of AR signaling inhibitor
enzalutamide (formerly MDV3100) (2012, FDA), which have demon-
strated efﬁcacy against chemotherapy-resistant CRPC with median in-
crease in survival of 4–5 months (de Bono et al., 2011; Ryan et al., 2013;
Scher et al., 2010, 2012). However, nearly all CRPC patients inevitably de-
velop acquired resistance to the second generation anti-AR signaling axis
treatments within ~6–12 months (Claessens et al., 2014). Signiﬁcantly,
approximately 20 to 40% of CRPC patients do not initially respond to
abiraterone or enzalutamide with respect to prostate-speciﬁc antigen
(PSA) levels (de Bono et al., 2011; Ryan et al., 2013; Scher et al., 2010,
2012), suggesting a subset of CRPC possesses de novo/innate resistance
to next-generation anti-AR axis therapies. Therefore, understanding the
molecular mechanisms underlying the innate/acquired resistance tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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a better stratiﬁcation of CRPC patients, rational designing of innovative
and cost-effective personalized therapeutic strategies for them, as well
as the discovery of novel therapeutics for overcoming resistance.
Beside the AR signaling axis, accumulating evidence suggests that im-
portant fundamental genetic alterations, such as loss of tumor suppressor
genes PTEN and/or TP53, might play a crucial role in the development of
CRPC (Chen et al., 2005; Lunardi et al., 2013; Wang et al., 2014). Recent
advances in whole-genome/exome sequencing analyses reveal that
PTEN and TP53 are often co-deleted or co-mutated in lethal CRPC
(Grasso et al., 2012). A systematic and multi-institutional study of meta-
static CRPC specimens has shown that 60 cases (40%) have PTENmuta-
tions, 75 cases (50%) have TP53 mutations, and 34 cases (22.7%) have
co-occurrence of PTEN and TP53mutations in the 150 cases of metastatic
CRPC (Robinson et al., 2015). Importantly, tracking the clonal origin of le-
thal prostate cancer through patient samples collected during tumor pro-
gression and at the time of death identiﬁed that the lethal metastatic
clone arose from primary prostate cancer cells carrying PTEN deletion
and mutant p53 (Haffner et al., 2013). Systems bioinformatics analyses
estimate that prostate cancers with combined loss of PTEN and TP53
make up 11% of highly aggressive prostate cancers and they bestow the
worst survival outcome for patients (Markert et al., 2011). Strikingly, 4
out of 6 CRPC patients-derived prostate cancer organoid lines carry co-
mutations of PTEN/TP53 (Gao et al., 2014). In support of the clinical ﬁnd-
ings that co-deletion/−mutation of PTEN/TP53 in prostate epithelial cells
plays a causal role in prostate tumorigenesis, mouse genetic studies sug-
gest that Pten deletion in prostate epithelial cells primarily initiates PIN,
whereas p53 loss in prostate epithelial cells is not sufﬁcient to cause
any distinguishable morphological phenotypes in vivo. However, double
deletion of Pten and p53 in murine prostate epithelial cells leads to inva-
sive prostate cancer (Chen et al., 2005;Wang et al., 2014)which develops
into CRPC with innate or de novo resistance to conventional ADT in vivo
(Lunardi et al., 2013). Thus, utilizing the Pten−/−p53-deﬁcient CRPC
model that recapitulates the salient features of a subset of human CRPC
to explore effective and selective means of killing prostate cancer cells
in vivo is a critical step to develop novel therapeutic strategies to success-
fully treat the CRPC patients harboring PTEN/TP53mutations.
On the basis of our genetic ﬁndings that hexokinase 2 (HK2)-medi-
ated aerobic glycolysis, known as the Warburg effect, drives prostate
tumor growth in xenograft model bearing Pten−/p53-deﬁcient murine
or human prostate cancer cells (Wang et al., 2014), we designed
preclinical studies to determine the therapeutic efﬁcacy on Pten−/
p53-deﬁciency-driven prostate tumorigenesis by pharmacologically
co-targeting HK2-mediated Warburg effect and ULK1-dependent au-
tophagy in genetic mouse models. We report here that pharmacologic
inhibition of HK2 enzymatic activity with 2-deoxyglucose (2-DG) phos-
phorylates AMPKwhich inhibits mTORC1-S6K1 translation axis to pref-
erentially reduce anti-apoptotic protein MCL-1 synthesis to prime
intrinsic apoptosis while simultaneously induces ULK1-dependent
pro-survival autophagy to counteract the apoptotic action of anti-
Warburg effect. Accordingly, co-targetingHK2-mediated aerobic glycol-
ysis with 2-DG and ULK1-driven autophagy with chloroquine (CQ) se-
lectively kills cancer cells through apoptosis to cause signiﬁcant tumor
regression in xenograft, leads to near-complete tumor suppression
and signiﬁcantly extends survival in Pten−/p53-deﬁciency-driven
CRPCmousemodels. Thus, our preclinical studies suggest an innovative
and efﬁcacious therapeutic strategy for the subsets of currently incur-
able CRPC carrying PTEN and TP53mutations.
2. Results
2.1. Inhibition of HK2-mediated Warburg effect activates AMPK-dependent
autophagy
Our previous genetic studies have shown that depletion of HK2 in-
hibits Pten−/p53-deﬁciency-driven prostate cancer growth inxenograft mouse models (Wang et al., 2014). The underlying mecha-
nism is due to reduction of cell proliferation rather than induction of ap-
optosis. Given that autophagy plays a controversial but important role
in response to cancer treatment (Mathew et al., 2007), we examined
whether genetic targeting HK2 would regulate autophagy in prostate
cancer cells. During autophagy, LC3-I (cytosolic form) is modiﬁed by
lipids to the faster migrating LC3-II membrane-bound lipidated form,
which is conjugated to phosphatidylethanolamine and incorporated
into the autophagosomal membrane. Therefore, active autophagy can
be measured by monitoring LC3-II by immunohistochemistry (IHC)
and Western blots, and by microscopy using ﬂuorescent protein–
tagged LC3 (GFP-LC3) (Mizushima et al., 2010). We found that LC3-II
detected by IHC was increased in xenografts carrying human PTEN−/
p53-deﬁcient PC3 cells with HK2 depletion by shRNAs (Fig. 1A), sug-
gesting HK2 depletion in PC3 cell-derived xenografts activated autoph-
agy. Since the serine/threonine kinase AMPK plays a crucial role in
metabolic stress-induced autophagy (Hardie et al., 2012), we examined
whether genetic inhibition of Warburg effect through HK2 depletion is
sufﬁcient to induce AMPK-dependent autophagy. HK2 reduction by
shRNAs in tumors activated AMPK, as indicated by the phosphorylated
AMPKα (the catalytic subunit of AMPK) at threonine 172 (Fig. 1A).
Knockdown of AMPKα by shRNA in PC3 cells signiﬁcantly reduced
LC3-II levels as determined by Western blot in HK2-depleted prostate
cancer cells (Fig. 1B). Notably, depletion of HK2 in PC3 cells stably ex-
pressing GFP-LC3 increased puncta formation of GFP-LC3 (Fig. 1C and
D). Conversely, depletion of AMPKα by shRNA dramatically reduced
the puncta formation of GFP-LC3 (Fig. 1C and D). These results together
suggest that genetic inhibition of HK2-mediated aerobic glycolysis leads
to AMPK-dependent autophagy in prostate cancer cells.
We next tested if these genetic phenotypes could be replicated with
the pharmacologic inhibition of HK2 enzymatic activity by 2-
deoxyglucose (2-DG). As expected, 2-DG inhibited aerobic glycolysis
as indicated by the signiﬁcant reduction of glucose consumption and
lactate production in PC3 cells (Fig. 1E and F). 2-DG profoundly reduced
cell proliferation (Fig. 1G). Flow cytometry analyses indicated a signiﬁ-
cant reduction of cells with S phase cells and an increase of cells with
G1 arrest, but no appreciable effect on apoptosis as minimal increase
in sub-G1 population was observed (Fig. 1H). Importantly, 2-DG in-
duced time-dependent increase of LC3-II levels (Fig. S1A, upper panel)
and increased the formation of autophagosomes manifested as the in-
crease of GFP-LC3 puncta in PC3 cells stably expressing GFP-LC3
(Fig. S1B and C). As LC3-II accumulation could also occur due to dysfunc-
tional late-autophagic processes such as inhibition of lysosomal degra-
dation, we treated PC3 cells with 2-DG alone or in combination with
two lysosomal inhibitors (E64d and pepstatin A) (Mizushima et al.,
2010). 2-DG combined with E64d/pepstatin A increased the level of
LC3-II compared with cells treated with 2-DG only (Fig. S1A, lower
panel). Thus, consistent with our observations from genetic ablation of
HK2, pharmacologic inhibition of HK2-mediated aerobic glycolysis
with 2-DG in PC3 cells led to a reduction in cell proliferation and an ac-
tivation of autophagy, but had minimal effects on cell apoptosis.
We then determined whether 2-DG-induced autophagy also
depended on AMPK in PC3 cells. 2-DG induced a time-dependent
AMPK phosphorylation (Fig. 1I). AMPK knockdown reduced LC3-II in
PC3 cells (Fig. 1J) and GFP-LC3 puncta formation in PC3-GFP-LC3 cells
upon 2-DG challenge (Fig. 1K). Collectively, these ﬁndings support
that genetic or pharmacologic targeting HK2-mediated Warburg effect
inhibits cancer cell proliferation and promotes AMPK-dependent au-
tophagy with negligible impact on apoptosis.
2.2. Inhibition of autophagy converts 2-DG-induced cell cycle arrest into
apoptosis in prostate cancer cells
To dissect the role of AMPK-dependent autophagy in 2-DG-
mediated cellular resposes in PC3 cells, we measured cell viability
upon genetic or pharmacologic inhibition of autophagy. When the
Fig. 1. Targeting HK2 in prostate cancer cells induces AMPK-dependent autophagy. (A–D) Depletion of HK2 activates AMPK-mediated autophagy. (A) Representative images of IHC
staining of HK2, LC3-II, and phosphorylated AMPK are shown in xenografts carrying PC3 cells stably expressing scramble or shRNAs for HK2. (B) PC3 cells were transfected with HK2
shRNA (shHK2) and/or AMPK shRNA (shAMPK). Lysates from the cells were immunoblotted by the indicated antibodies. (C) Representative images of GFP-LC3 translocation in PC3-
GFP-LC3 cells expressing shRNAs for HK2 and/or AMPK. (D) Quantiﬁcation of GFP-LC3 translocation from the representative images shown in C. (E–K) Pharmacologic inhibition of
HK2 suppresses Warburg effect-mediated cell proliferation and induces AMPK-dependent autophagy. (E) Glucose consumption and (F) lactate production for PC3 cells treated with
vehicle only (Con) or 2-DG (20 mM). (G) Cell proliferation and (H) cell cycle distribution determined by ﬂow cytometry in PC3 cells treated with vehicle only or 2-DG.
(I) Immunoblots of lysates from PC3 cells treated with 2-DG (20 mM) for the indicated times. (J) Lysates from PC3 cells stably expressing scramble or AMPK shRNA treated with
vehicle or 2-DG for 24 h were immunoblotted by the indicated antibodies. (K) Quantiﬁcation of GFP-LC3 translocation is shown in PC3-GFP-LC3 cells expressing scramble shRNA
(Con) and/or AMPK shRNA (shAMPK) upon 2-DG challenge. At least 500 cells were counted for each experimental repeat. For western blot, tubulin was used as a loading control. All
data are shown as means ± SEM. *P ≤ 0.01. Scale bar = 50 μm unless otherwise indicated. See also Fig. S1.
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BECLIN1, were effectively depleted by shRNAs, 2-DG treatment signiﬁ-
cantly induced prostate cancer cell apoptosis, as demonstrated by the
increase of cleaved PARP levels, and a 45% or greater reduction of cell vi-
ability (Fig. 2A–C and S2A-C). Knocking down ULK1, a critical down-
stream target involved in AMPK-regulated autophagy (Kim et al.,
2011), cooperated with 2-DG to reduce cell viability and identicalresults were obtained as PC3 cells expressing shRNAs for ATG5, ATG7
and BECLIN1 (Fig. 2D and S2D). These data suggest that PTEN−/p53-
deﬁcient PC3 cells utilize AMPK-ULK1-dependent autophagy as a cell
survival mechanism against 2-DG-mediated anti-glycolysis treatment.
To demonstrate this possibility pharmacologically, we used chloroquine
(CQ) to prevent lysosomal fusion with autophagosomes to block au-
tophagy (Rubinsztein et al., 2007). No appreciable cell death was
Fig. 2. Inhibition of autophagy converts 2-DG-mediated cell cycle arrest into mitochondria-dependent apoptosis in prostate cancer cells. (A–D) Genetic inhibition of autophagy sensitizes
cancer cells to apoptosiswith 2-DG. Lysates from PC3 cells expressing shRNAs for ATG5 (A), ATG7 (B), Beclin 1(C), and ULK1 (D)were immunoblottedwith the indicated antibodies. (E–I)
Pharmacologic inhibition of autophagy by CQ collaborateswith 2-DG to induce intrinsic apoptosis. (E) Representative images of phase photomicrographs of PC3 or RWPE-1 cell viability in
the absence (Con) or presence of 2-DG (20mM), CQ (50 μM) or 2-DG plus CQ for 36 h are shown. (F) Lysates from PC3 and RWPE-1 cells upon 2-DG and/or CQ treatment were subject to
immunoblottingwith the indicated antibodies. (G) Immunoblots of lysates fromRWPE-1 cells stably expressing scramble or PTEN shRNA upon 2-DG and/or CQ treatment for 48 h. Tubulin
serves as a loading control for Western blot. Scale bar = 100 μm. See also Fig. S2.
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thelial RWPE-1 cells treated with 2-DG or CQ alone, however, the
combination induced remarkable apoptosis in PC3 cells, but not in
RWPE-1 cells (Fig. 2E, F and S2E). These ﬁndings indicated that the
combination therapy preferentially killed prostate cancer cells over
non-cancerous prostate epithelial cells. This selectivity might be
due to the addiction of PTEN−/p53-deﬁcient prostate cancer cells
to HK2-mediated Warburg effect, and consequently autophagy for
cell survival when Warburg effect was inhibited. If true, PTEN deple-
tion in the p53-inactive, non-tumorigenic RWPE-1 cells should ren-
der these genetically-manipulated cells with enhanced HK2
expression (Wang et al., 2014) sensitive to the combination treat-
ment. Indeed, treating PTEN-depleted RWPE-1 cells with 2-DG and
CQ induced signiﬁcant apoptosis (Fig. 2G and S2F).
2.3. 2-DG primes mitochondria for apoptosis through AMPK-mTORC1-
MCL1 signaling in prostate cancer cells
Given that induction of autophagy compromises apoptosis upon 2-
DG-mediated anti-glycolysis treatment, we expect that inhibition of
AMPK-dependent autophagy by depletion of AMPK sensitizes cancer
cells to 2-DG. Surprisingly, in contrast to ULK1-depleted PC3 cells with
2-DG treatment (Fig. 2D), no appreciable apoptotic PARP cleavage was
observed in AMPK-depleted PC3 cells upon 2-DG challenge (Fig. 3A
and B). These results prompted us to test the possibility that activation
of AMPK with 2-DG initiates a signaling pathway to sensitize cancer
cells for apoptosis while induction of AMPK-ULK1-dependent autopha-
gy protects cancer cells from apoptosis. Consistent with earlier studies
that activated AMPK inhibits mTORC1 signaling (Hardie et al., 2012),
phosphorylation of p70S6K, a critical downstream effector of mTORC1
axis in the regulation of translation (Thoreen et al., 2012), was signiﬁ-
cantly reduced, mirror opposite of activated AMPK in 2-DG-treated
PC3 cells (Fig. 3C). Notably, selective reduction of mitochondrial BCL2
family members of anti-apoptotic protein MCL-1, but not BCL-2 andBCL-xl or pro-apoptotic protein BAX or BAK, was observed in PC3 cells
treated with 2-DG (Fig. 3C). Depletion of AMPK signiﬁcantly attenuated
2-DG-caused reduction of phosphorylated p70S6K and partially re-
stored MCL-1 protein expression (Fig. 3D). However, knockdown of
p70S6K reduced MCL-1 protein expression but not mRNA abundance
(Fig. 3E and data not shown), consistent with previous observation
that MCL-1 can be translationally regulated by mTOR signaling in cer-
tain cancer cells (Mills et al., 2008). Moreover, exogenous overexpres-
sion of MCL-1 dramatically inhibited apoptosis induced by
combination of 2-DG and CQ in PC3 cells (Fig. 3F). These ﬁndings
collectively indicate that AMPK suppression of mTORC1-p70S6K-MCL-
1 axis plays a critical role in transducing 2-DG-induced metabolic stress
signal to prime mitochondria for cell death while AMPK induction of
ULK1 signaling counteracts the apoptotic action of anti-glycolysis (Fig.
3G). Thus, inhibition of AMPK downstream ULK1-mediated autophagy,
but not AMPK itself, favors cell apoptosis caused by reduction of MCL-1
resulting from AMPK suppression of mTORC1 signaling upon 2-DG
treatment.
2.4. Pharmacologic co-targeting Warburg effect and autophagy causes tu-
mor regression in xenograft model carrying PC3 cells
On the basis of our aforementioned cell culture ﬁndings, we rea-
soned that co-targeting HK2-mediated Warburg effect with 2-DG and
ULK1-dependent autophagy with CQ in vivo would induce cancer cell
apoptosis to suppress human prostate tumor growth. To this end, we
established xenograft model using human PC3 cells. The NSGmice har-
boring the PC3 tumor xenografts of approximately 50 mm3 were ran-
domly assigned to the following four groups: PBS (control), 2-DG, CQ,
or 2-DG plus CQ. Monotherapy with 2-DG or CQ caused a moderate in-
hibition of tumor growth, but was incapable of causing tumor regres-
sion (Fig. 4A–C). In contrast, combination therapy with 2-DG and CQ
caused signiﬁcant regression of established PC3 tumor xenografts (Fig.
4A–C). Analyses of the PC3 xenografts showed that the percentage of
Fig. 3. Activation of AMPK-S6K-MCL-1 Signaling Sensitizes Cancer Cells to Apoptosis upon 2-DG Treatment. (A) Lysates from PC3 cells expressing shRNAs for scramble or AMPK were
immunoblotted with the indicated antibodies upon 2-DG treatment. P indicates positive control lysates for cleaved PARP. (B) Quantiﬁcation of cell viability from PC3 cells stably
expressing scramble or AMPK shRNA upon 2-DG treatment for 48 h. PC3 cells-shULK1 serves as positive control. (C) Immunoblots of lysates with indicated antibodies from PC3 cells
treated with 2-DG at different time courses. (D) Lysates from PC3 cells expressing scramble or AMPK shRNAs treated with 2-DG and CQ were immunoblotted by the indicated
antibodies. (E) Lysates from PC3 cells expressing scramble or p70S6K1 shRNAs were immunoblotted by the indicated antibodies. (F) Lysates from PC3 cell expressing vector or
exogenous MCL-1 treated with vehicle or 2-DG were immunoblotted by the indicated antibodies. (G) Schematic model of 2-DG-induced AMPK phosphorylation regulates autophagy
and apoptosis. Tubulin served as a loading control for Western. Data are shown means ± SEM. All the cell viability experiments are repeated three times. *P ≤ 0.01.
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both drugs, while the percentage was only 2.4% and 2.1% in those treat-
ed with 2-DG or CQ, respectively (Fig. 4D and F), although inhibition of
cell proliferation upon individual treatment was comparable with the
combination treatment as evident by signiﬁcantly decreased Ki-67 pos-
itive cells (Fig. 4D and E). Therefore, the combination of 2-DG and CQ
in vivo causes an effective tumor regression through the induction of
cancer cell apoptosis in the xenograft model carrying PC3 cells.
2.5. Loss of Pten and p53 in murine prostate epithelium leads to tumor
growth independent of AR signaling in xenograft model
To test whether Pten−/p53-deﬁciency confers to murine prostate
cancer cells the abilities to develop innate resistance to ADT in xenograft
mouse models, the UMN-4240P mouse cell lines derived from Pten−/
p53-deﬁcient prostate tumors (Wang et al., 2014) were injected into
the ﬂank of non-castrated and surgically-castrated male NSG mice,
and tumor growth was monitored weekly. No difference was observed
for tumor size, tumor weight, cellular proliferation marker Ki-67, andapoptotic marker cleaved caspase 3 in xenografts derived from non-
castrated and castrated male NSG mice (Fig. S3A–E).
Given that AR plays an important function in the development of
CRPC (Chen et al., 2004),we utilizedUMN-4240Pmouse cancer cells ex-
pressing endogenous Ar to determine its role in Pten/p53-deﬁciency-
driven CRPC in vivo. Lentivirus-mediated shRNAs for Ar efﬁciently re-
duced Ar expression in UMN-4240P cells, but did not affect cell prolifer-
ation and/or apoptosis (Figs. S3F and 3G). Importantly, the UMN-4240P
cells stably expressing lentivirus-mediated shRNAs for Ar or empty vec-
tor (control) implanted into the ﬂanks of castratedmale NSGmice grew
at identical rate as the vector-infected controls as indicated by tumor
size and weight (Figs. S3H and 3I). No difference was observed for Ki-
67 and cleaved caspase 3 in xenograft tumors harboring vector or
shRNAs for Ar (Fig. S3J–L). Consistent with the genetic studies, pharma-
cologic inhibition of the AR signaling axis by the second generation AR
antagonist drug enzalutamide had no detectable effect on the inhibition
of cell proliferation and tumor growth in xenograft mouse models, as
evaluated by tumor growth (Fig. 5A–C). These ﬁndings together support
that Pten−/p53-deﬁciency confers to the prostate cancer cells intrinsic
Fig. 4.Co-targetingWarburg effect and autophagy causes tumor regression inhumanCRPC xenograftmousemodel. (A) Representative images of tumor sizes after 4weeks of treatment as
indicated. (B) Quantiﬁcation of tumor weight of PC3 xenografts as shown in (A). The horizontal line represents the average tumor weights for each group. (C) Tumor volumes were
measured once per week and plotted as a function of time. Each data point represents average tumor volume for the indicated treatment group. (D) Representative IHC images of Ki-
67 and cleaved caspase 3 (C-caspase 3) in PC3 xenografts from (A) are shown to assess tumor cell proliferation and apoptosis. (E) Quantiﬁcation of Ki-67 positive cells in PC3
xenografts shown in (D). (F) Quantiﬁcation of cleaved caspase 3 positive cells in PC3 xenografts shown in (D). All data are means ± SEM. *P ≤ 0.01. Scale bar = 50 μm.
55L. Wang et al. / EBioMedicine 7 (2016) 50–61resistance to ADT and leads to prostate tumor growth bypassing the re-
quirement of AR signaling axis in xenograft.
2.6. Co-targeting Warburg effect and autophagy inhibits tumor growth in
xenograft model carrying murine Pten−/p53-deﬁcient prostate cancer
cells
Since our genetic studies have shown that HK2 is required for Pten/
p53-deﬁciency-driven tumor growth of UMN-4240P cells (Wang et al.,
2014), we speculated that pharmacologic inhibition of HK2-mediated
Warburg effect with 2-DG and ULK1-dependent autophagy with CQ
should suppress CRPC tumor growth in xenograft models carrying
UMN-4240P cells. To this end, male NSG mice bearing UNN-4240P
tumor xenografts of approximately 100 mm3 were randomly assigned
to the following two groups: PBS (control) and 2-DG plus CQ. Combina-
tion therapy with 2-DG and CQ reduced tumor size and weight in treat-
ed mice compared with control group (Fig. 5D and E). Analyses of the
residual xenograft tumors showed that the percentage of cancer cells
positive for Ki-67 and cleaved caspase 3 was about 20% and 12% in
NSG mice treated with both drugs, while the percentage is around
65% and less than 2% in those control mice group treated with PBS, re-
spectively (Fig. 5F–H).
2.7. Co-targeting Warburg effect and autophagy robustly suppresses
Pten−/p53-deﬁciency-driven CRPC in genetic mouse model
To validate the de novo CRPC phenotype reported by Lunardi A
et al. as the result of double loss of Pten and p53 in murine prostate
epithelium, which was completely resistant to surgical castration
and the classical AR antagonist drug bicalutamide (Lunardi et al., 2013),
we castrated Pten- and p53-double deﬁcient mice by surgically removingthe testes and epididymis at 12 weeks of age. Castration did not inhibit
tumor growth and progression, as demonstrated by no histopathology
changes and no signiﬁcant reduction of prostate tumor weight in the cas-
trated Pten−/p53-deﬁcient mice compared to the non-castrated controls
(Figs. S4A and 4B). Given the advantage of second generation anti-AR
drug enzalutamide compared to bicalutamide (Tran et al., 2009), we deter-
mined the therapeutic efﬁcacy of enzalutamide on Pten−/p53-deﬁciency-
drivenCRPC ingeneticmousemodel. Enzalutamidehadminimal orno sup-
pression of Pten−/p53-deﬁciency-driven CRPC in GEMMs, as evidenced by
nohistopathologychanges andno reductionofprostate tumorweight com-
pared to the vehicle-treated controls (Figs. S4A and 4C). These ﬁndings
fromgeneticmousemodels togetherwith genetic andpharmacologic stud-
ies in xenografts (Figs. S3 and S4) collectively support that loss of Pten and
p53 in prostate epithelium leads to AR-independent CRPC, which is de novo
resistant to second generation ADT in vivo.
Based on our genetic studies (Wang et al., 2014) and combination
therapeutic ﬁndings in PC3/UMN-4240P xenograft models, we tested
co-targeting HK2-mediated aerobic glycolysis with 2-DG and ULK1-
dependent autophagy with CQ for killing ADT-resistant prostate cancer
cells to suppress in situ prostate tumorigenesis in our autochthonous
Pten−/p53-deﬁciency-driven CRPC mouse model by administering
PBS (control) or combination of 2-DG and CQ daily for 5 days a week
for 4 weeks starting at 12 weeks of age when signiﬁcant pathological
features of invasive prostate cancer were observed (Fig. S5 and (Lu
et al., 2015; Xie et al., 2014)). In contrast to lack of efﬁcacy of the ADT,
the combination therapy led to a marked reduction in prostate tumor
size and weight. Histopathological analysis of combination-treated
Pten/p53 double-deﬁcient mice identiﬁed signiﬁcant normal prostate
epithelium and a profound normalization of histopathological pheno-
type that was almost identical to normal prostate (Fig. 6A–C). In line
with the mechanistic ﬁndings in xenografts, the residual prostate cells
Fig. 5. Co-targetingWarburg effect and autophagy suppresses tumor growth of Pten−/p53-deﬁciency-driven CRPC in xenograft models. (A–C) Effects of enzalutamide on prostate cancer
cell proliferation and tumor growth in xenograft model: (A) Cell proliferation upon enzalutamide treatment. (B) Colonies were stained by crystal violet after 10 days of cell growth.
(C) Tumor growth curve in xenografts carrying UMN-4240P cells treated by vehicle or enzalutamide for 4 weeks. (D–H) Combination therapy with 2-DG and CQ signiﬁcantly
suppresses tumor growth in xenograft mouse models carrying UMN-4240P cells. (D) Representative images of tumor size after 4 weeks of treatment as indicated. (E) Quantiﬁcation of
tumor weight of tumors as shown in (D). (F) Representative hematoxylin/eosin staining, IHC images of Ki-67 and cleaved caspase 3 (C-caspase 3) in tumors from (D) are shown to
assess tumor cell proliferation and apoptosis. (G) Quantiﬁcation of Ki-67 positive cells in tumors shown in (F). (H) Quantiﬁcation of cleaved caspase 3 positive cells in tumors shown
in (F). All data are means ± SEM. *P ≤ 0.01. ns: not statistically signiﬁcant. Scale bar = 25 μm. See also Fig. S3.
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indicated by the reduction of Ki67-positive cells (Fig. 6D) and in-
creased cleaved-caspase 3-mediated cancer cell apoptosis (Fig. 6E
and F). Signiﬁcantly for selectivity, we did not ﬁnd appreciable ap-
optosis in the prostate epithelial cells of 2-DG/CQ-treated age-
matched wild-type mice, evident by the lack of cleaved caspase 3
in comparison with 2-DG/CQ-treated Pten−/p53-deﬁcient mice
(Fig. S6A). No notable adverse effect on body weight was observed
up to 40 weeks treatment with 2-DG and CQ in vivo (Fig. S6B). No-
tably, the control (vehicle-treated) mice all died in 7 months as
previously reported (Chen et al., 2005). However, all the
combination-treated mice survived for over one year (Fig. 6G, H),
suggesting the long-term in vivo treatment with 2-DG plus CQ re-
markably extended survival beneﬁt in Pten−/p53-deﬁcient pros-
tate cancer mouse models.
Therefore, our preclinical studies in Pten−/p53-deﬁcient prostate
cancer mouse models suggest an efﬁcacious and novel therapeutic
strategy for the subset of “second generation”ADT-resistant CRPC carry-
ing PTEN and TP53mutations.
2.8. HK2 as a potential therapeutic target for human CRPC
Our previous studies have shown that HK2 protein abundance is
elevated in human prostate cancer tissues, and particularly in
human prostate cancers carrying PTEN and TP53 mutations (Wanget al., 2014). Integrative analysis of “Grasso Dataset” (Grasso
et al., 2012) using the “cBioPortal” (Cerami et al., 2012; Gao et al.,
2013) revealed that mutant PTEN co-occurrence with mutant TP53
was signiﬁcantly increased compared to wild-type PTEN coexisting
with mutant TP53 in CRPC (P = 0.0235, X2 test), and the frequency
of co-deletion or -mutation of PTEN and TP53 was 32% (16/50) in
CRPC specimens (Fig. 7A). We also examined whether HK2 overex-
pression could be observed from available CRPC dataset. Since
equivalent proteomic data are not yet available for human CRPC
specimens, we used mRNA data, despite imperfect correlation be-
tween HK2 protein and HK2 mRNA, by Oncomine analysis of
human lethal CRPC dataset (Grasso et al., 2012). HK2 mRNA was
signiﬁcantly increased in CRPC compared to the primary prostate
cancer (PCA) (Fig. 7B). Most importantly, the elevated HK2 mRNA
expression level in CRPC was signiﬁcantly associated with high
mortality of the patients (Fig. 7C) and with reduced survival after
ﬁrst chemotherapy for patients (Fig. 7D). These data suggest that
HK2 may serve as a stratiﬁcation diagnostic and/or prognostic
marker and a therapeutic target for CRPC with our combined mo-
dality. Therefore, our “proof-of-principle” studies in the preclinical
CRPC mouse models provide compelling evidence that co-targeting
HK2-mediated Warburg effect with 2-DG and ULK1-dependent au-
tophagy with CQ could be developed into an innovative personal-
ized therapeutic strategy for currently incurable CRPC patients
whose tumors have elevated HK2 expression (Fig. 7E).
Fig. 6. Co-targetingWarburg effect and autophagy suppresses tumor growth of Pten−/p53-deﬁciency-driven CRPC in preclinicalmousemodels. (A–F) Short-term (4weeks) combination
therapy robustly inhibits prostate tumor growth in Pten−/p53-deﬁcienent mouse model. (A) Representative images of tumor size of prostate tumor in control and 2-DG plus CQ-treated
PtenΔ/Δp53Δ/Δ mice at age of 16 weeks. (B) Bar graph showed prostate tumor weight in control and 2-DG plus CQ treated PtenΔ/Δp53Δ/Δ mice (n = 6). (C) Representative images of
haematoxylin/eosin staining of anterior prostates from D. (D) Quantiﬁcation of Ki-67 positive cells to assess prostate tumor cell proliferation in control and 2-DG plus CQ treated PtenΔ/
Δp53Δ/Δ mice. (E) Representative IHC images of cleaved caspase 3 in prostate tumors upon combination treatment. (F) Quantiﬁcation of cleaved caspase 3 positive cells to assess
tumor cell apoptosis from E. (G, H) Long-term in vivo combination treatment remarkably extends survival in Pten−/p53-deﬁcienent mouse model. (G) Treatment schedule.
(H) Survival curves of Pten−/p53-deﬁcienent mouse cohorts treated by vehicle (control) or 2-DG and CQ (n = 10). All data are means ± SEM. *P ≤ 0.01. Scale bar = 25 μm. See also
Figs. S4-S6.
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Resistance to the second generation anti-AR axis therapy is a se-
rious therapeutic hurdle for CRPC patients (Claessens et al., 2014).
Here we report that loss of Pten and p53 in prostate epithelial
cells, occurring in 20–30% of human CRPC, leads to de novo
murine CRPC that is completely resistant to second generation
ADT. In contrast, mechanism-driven co-targeting HK2-mediated
Warburg effect with 2-DG and ULK1-dependent autophagy with
CQ markedly kill such CRPC cells to suppress tumor growth by se-
lectively inducing apoptosis in multiple independent yet comple-
mentary preclinical models.
AMPK is a highly conserved Ser/Thr protein kinase complex that sits
at a central node in maintaining cellular energy homeostasis by activat-
ing catabolic metabolism and inhibiting anabolic metabolism in re-
sponse to metabolic stress (Hardie et al., 2012; Oakhill et al., 2012).
We have shown here that pharmacological or genetic inhibition of
HK2 causes AMPK phosphorylation at Thr 172, an indicator of activatedAMPK, which might be due to reduction of ATP ((Patra et al., 2013; Wu
et al., 2015). However, the role of activated AMPK in tumorigenesis is
less clear, as both oncogenic and tumor suppressor functions have
been reported (Liang and Mills, 2013). During cancer treatment, the
role of AMPK also remains controversial (Liang andMills, 2013). The pos-
sible reasons might be that catalytically active AMPK phosphorylates a
plethora of substrates that transduce multiple signals for various cellular
responses associated with tumor development and cancer therapy. Our
mechanistic studies revealed that activated AMPK functions as a
double-edged sword in prostate cancer cells in response to 2-DG-
induced metabolic stress. Activation of AMPK induces ULK1-dependent
autophagy to protect cells from apoptosis while concomitantly inhibits
mTORC1 signaling to reduceMCL-1 protein synthesis to primemitochon-
dria for apoptosis. These ﬁndings provide a strong theoretical rationale
for precision targeting of AMPK downstream ULK1-mediated autophagy,
rather than AMPK itself, to achieve desired therapeutic outcome.
Our studies provided compelling evidence to support that pharma-
cologic co-targeting HK2-mediated Warburg effect with 2-DG and
Fig. 7. Expression of HK2 in human CRPC and correlates with patient survival. (A) OncoPrint of mutant frequency of PTEN and TP53 in human castration-resistant prostate cancer.
(B) Oncomine boxed plot of HK2 expression at mRNA levels between primary prostate cancer (PCA) and CRPC in dataset Grasso et al. (2012). (C) Correlation between HK2 mRNA
expression level and overall survival follow-up time for CRPC patients. (D) Correlation between HK2mRNA expression level and survival after ﬁrst chemotherapy for CRPC patients.
Based on median expression of HK2 in all the CRPC patients from “Grasso dataset”, the CRPC patients were separated into high HK2 (above median: Red line) and Low HK2 (Below-
median: Blue line) expression. Then, Kaplan–Meier survival analysis of patient cohorts is performed to analyze the survival. The difference of survival is determined by log-rank test.
(E) Schematic model depicting co-targeting Warburg effect and autophagy inhibits tumor growth of CRPC in vivo. *P ≤ 0.01.
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Pten−/p53-deﬁciency-driven CRPC in vivo. Whereasmonotherapywith
2-DG or CQ inhibits prostate tumor growth by reducing cell prolifera-
tion, combination therapy with 2-DG and CQ causes signiﬁcant tumor
regression by inducing robust cancer cell apoptosis in xenograft models
carrying Pten−/p53-deiﬁcient mouse and human prostate cancer cells
and in a spontaneous prostate cancermousemodel. Notably, the combi-
nation treatment selectively kills cancer cells by apoptosiswhile sparing
normal prostate epithelial cells. This selective cytotoxicity towards
Pten−/p53-deﬁcient CRPC cells is due to their addiction to HK2-
mediated Warburg effect for tumor growth (Wang et al., 2014) and
their dependence on ULK1-induced autophagy for cell survival when
HK2 glycolytic enzyme activity is inhibited.
Interestingly, dataset analyses show that HK2 is highly expressed in
CRPC compared to the primary prostate cancer. Our ﬁndings thus pro-
vide preclinical proof-of-concept that co-targeting Warburg effect
with 2-DG and autophagy with CQ could be extended to effectively
treat CRPC patients whose tumors have elevated HK2 expression.
Since recent genetic studies revealed that HK2 is required for oncogenic
Kras-driven lung tumorigenesis and ErbB2-driven mammary gland tu-
morigenesis in vivo (Patra et al., 2013), our therapeutic strategy for
HK2-mediated prostate cancers may also be extendable to treating
HK2-dependent lung and breast cancers.As far as the tolerability is concerned, accumulating evidence sug-
gests that 2-DG exhibits anti-tumor activity in mouse and rat cancer
models in vivo at dosageswithout toxicity to the host animals, including
models of sarcomas, adenocarcinomas, leukemias, melanomas, and
bladder, colon, lung, and breast tumors (Xi et al., 2014). A recent
Phase I clinical trial (NCT00096707) in prostate cancer patients indicat-
ed that 2-DG at 63 mg/kg body weight was tolerable dose with anti-
tumor effect and was recommended for Phase II clinical Trial (Raez
et al., 2013). By allometric scaling, the dosage of 800mg/kg bodyweight
in mice used for our work here could be converted to a human dose of
65 mg/kg body weight (Reagan-Shaw et al., 2008). Thus, 2-DG dose
used in our animal studies approximates the safe range for translation
to patients.
The dosage of antimalarial drug CQ and/or its derivatives administrat-
ed in our animal studies is also well-tolerated in patients and had been
used in patients for decades. Currently, multiple clinical trials targeting
autophagy using CQ or its derivate hydroxychloroquine (HCQ) as
mono- or combination-therapy for tumors are under way (http://www.
cancer.gov/clinicaltrials). Importantly, no notable adverse physiological
consequences, monitored by body weight, are observed with long-term
administration of 2-DG and CQ in our mouse studies. Thus, building
upon insights gained from our ﬁndings in the preclinical models and
the clinical use knowledge of these two existing drugs, repurposing
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studies therefore have immediate implications for the design of clinical
trials to evaluate the combination treatment with 2-DG and CQ as a
novel targeted therapeutic strategy for the subsets of currently incurable
CRPC carrying PTEN and TP53mutations.4. Materials and methods
4.1. Generation and genotyping of Pten and/or p53 mutant mice
Experimental procedures were performed as previously described
(Wang et al., 2014). Conditional Ptenﬂox/ﬂoxmousewas generated as pre-
viously described (Zheng et al., 2008). The conditional p53ﬂox/ﬂoxmouse
was generously provided by Dr. A Berns (Jonkers et al., 2001). PB-Cre4
transgenic mice were obtained from the NCI Mouse Repository. Female
mice carrying Ptenﬂox/+p53ﬂox/+were crossedwithmalemiceharboring
PB-Cre4+Ptenﬂox/+p53ﬂox/+ to generate mutant mice with prostate
epithelium-speciﬁc deletion of Pten and/or p53. DNA from tail or pros-
tate tumors was used for PCR-based genotyping as reported (Wang
et al., 2014). All animal protocols were reviewed and approved by the
University of Minnesota Institutional Animal Care and Use Committee.4.2. Genotyping PCR reactions
For PB-Cre4: Primer 1 (5′-TCT GCA CCT TGT CAG TGA GG-3′) and
primer 2 (5′-GCA AAC GGA CAG AAG CAT TT-3′) were used.
Thermocycling conditions were 28 cycles of 94 °C for 45 s, 55 °C for
30 s and 72 °C for 1 min.
For p53Flox/Flox: Primer1 (5′-CAC AAA AAC AGG TTA AAC CCA G-3′)
and primer 2 (5′-AGC ACA TAG GAG GCA GAG AC-3′) were used. To de-
tect the deleted allele, Dp53 primer (5′-GAA GAC AGA AAA GGG GAG
GG-3′) and primer 1 were used. Thermo cycling conditions were 35 cy-
cles of 94 °C for 1 min, 60 °C for 45 s and 72 °C for 30 s.
For PtenFlox/Flox: Primer 1 (5′-CTT CGG AGC ATG TCT GGC AAT GC-3′)
and primer 2 (5′-CTG CAC GAG ACT AGT GAG ACG TGC-3′) were used.
To detect the deleted allele, DPten primer (5′-AAG GAAGAG GGT GGG
GAT AC-3′) and primer 1 were used. Thermo cycling conditions were
30 cycles of 94 °C for 1 min, 62 °C for 45 s and 72 °C for 1 min.4.3. Chemical compounds
Chemicalswere obtained from the following sources: 2-Deoxyglucose
(2-DG) and chloroquine (CQ), Sigma-Aldrich. Enzalutamide, Selleck or
APExBio. 2-DG and CQwere dissolved in PBS, at 1000 times the ﬁnal con-
centration used in vitro, and the freshly prepared 2-DG and CQ were ad-
ministered to mice by intraperitoneal injection at 800 mg/kg and
50 mg/kg in vivo, respectively. Enzalutamide was dissolved in DMSO at
1000 times the ﬁnal concentration used in experiments in vitro, and
Enzalutamide was dissolved in vehicle (1% carboxymethyl cellulose,
0.1% Tween-80, 5%DMSO) and given at a dose of 30mg/kg by oral gavage
in mice.4.4. Cell culture
RWPE-1 immortalized non-tumorigenic human prostate cells and
human prostate cancer cell lines (PC3, LNCaP and DU145) were obtain-
ed from American Type Culture Collection. RWPE-1 cells were main-
tained in Keratinocyte Serum Free Medium (K-SFM). PC3 cells were
maintained in F-12K supplemented with 10% fetal bovine serum.
LNCaP and DU145 cells were maintained in RPMI-1640 supplemented
with 10% fetal bovine serum. Mouse tumor derived polyclonal cancer
cells (UMN-4240P) were grown in DMEM containing 10% FBS at stan-
dard tissue culture condition.4.5. Cell viability and clonogenic survival assay
For cell viability assay, each well of a 12-well plate was seeded with
2 × 105 cells and the plates were incubated overnight to allow cells to
attach. After 48 h of drug treatment, the cell viability was determined
by trypan blue. For clonogenic survival assay, cells were plated in tripli-
cate at 2 × 104 cells per well of six-well tissue culture plate. After one to
two weeks of growth, cell colonies were ﬁxed in 10% formalin and
stained with crystal violet (0.05% w/v).
4.6. Cell cycle analysis
Cells were harvested, ﬁxed in ethanol, incubated with ribonuclease
and stained with propidium iodide. DNA content was determined on a
FACScan ﬂow cytometer (Beckman Coulter).
4.7. Glucose consumption and lactate production
PC3 cells were seeded at 1 × 105 cells per well in a 6-well plate and
incubated for 24 h to allow the cells to attach. The cells were then treat-
ed with vehicle only or 2-DG (20 mM) for 48 h. The glucose and lactate
concentrations in themedium during a period of 72 h were determined
using the Glucose Assay Kit (Eton Bioscience) and Lactate Assay Kit II
(Biovision), respectively. Glucose consumption was determined by the
difference between the original glucose concentration and the mea-
sured glucose concentration at 72 h. As themedium itself does not con-
tain lactate, the measured lactate concentration reﬂects the lactate
production by the cells. The values of glucose consumption and lactate
production were converted into actual rate.
4.8. Drug treatment in animal models
Xenograft mouse models carrying human prostate cancer PC3 cells
or mouse prostate cancer UMN-4240P cells were established in male
NSG mice as described (Wang et al., 2014). Treatment started once xe-
nograft tumors were established (the tumor volume reaches 50–
100 mm3). For PC3 xenografts, mice were randomly assigned into four
groups and treated with PBS (Control), 2-DG (800 mg/kg in PBS), CQ
(50 mg/kg in PBS), or 2-DG (800 mg/kg) plus CQ (50 mg/kg) by intra-
peritoneal injection (I.P.), daily for 5 days a week for 4 weeks. For
mice carrying xenografts of UMN-4240P cells, two groups were ran-
domly assigned and treated with PBS (Control) or 2-DG (800 mg/kg)
plus CQ (50 mg/kg) as described in xenograft models harboring PC3
cells. Then, the NSG mice carrying xenografts were euthanized and the
tumors were dissected, weighed and processed for histopathology and
biochemical analyses. To observe the short-term therapeutic efﬁcacy
in genetically engineered castration resistant prostate cancer mouse
model, six Pten/p53-deﬁcient mice at age of 12-weeks per group were
treated with PBS (Control) or 2-DG (800 mg/kg) plus CQ (50 mg/kg)
by I.P., daily for 5 days a week for 4 weeks. Mice were euthanized, and
prostate tumors were dissected, weighed and processed for histopa-
thology and biochemical analyses at the conclusion of these studies.
To determine survival beneﬁt upon long-term treatment, ten Pten/
p53-deﬁcient mice at age of 12-weeks per group were treated with
PBS (Control) or 2-DG (800 mg/kg) plus CQ (50 mg/kg) by I.P., daily
for 5 days a week until the mice were found moribund.
4.9. Androgen deprivation therapy in mice
For ADT in xenograft mouse models: male NSG mice at 10 weeks of
age were castrated by surgically removing the testes. After 2 weeks, the
UMN-4240P cells were injected into the ﬂank of non-castrated and sur-
gical castrated male NSG mice; or the UMN-4240P cells stably express-
ing lentivirus-mediated shRNAs for Ar or empty vector (control) were
implanted into the ﬂanks of male castrated NSG mice; or the NSG
mice carrying xenografts with tumor size reached approximately
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hicle (control) or enzalutamide at a dose of 30 mg/kg by oral gavage as
reported (Tran et al., 2009), daily for 5 days a week for 4 weeks and
tumor growthwasmonitored. Tumor sizewasmeasuredweekly in 2 di-
mensions (l ×w)with calipers and calculated by the following formula:
volume= (length ×width2)/2. At the endpoint of each experiment, the
NSG mice carrying xenografts were euthanized and the tumors were
dissected, weighed and processed for histopathology and biochemical
analyses. For ADT in genetic mouse model, Pten/p53-deﬁcient mice at
12 weeks of age were castrated by surgically removing the testes or
by using enzalutamide at a dose of 30 mg/kg by oral gavage as reported
(Tran et al., 2009), daily for 5 days aweek for 4weeks.Micewere eutha-
nized, and prostate tumors were dissected, weighed and processed for
histopathology and biochemical analyses at the conclusion of these
studies.
4.10. Immunoblotting
Cells were lysed with TEB150 buffer (50mMHEPES pH 7.4, 150mM
NaCl, 2 mMMgCl2, 5 mM EGTA pH 8.0, 1 mM dithiothreitol, 0.5% Triton
X–100, 10% glycerol, 1 mMNa3VO4, 1 μMmicrocystin–LR and protease/
phosphatase inhibitor cocktail). Lysates from mouse prostates were
prepared by homogenizing mouse prostates in modiﬁed RIPA buffer
(20mMTris–HCl pH 7.4, 150mMNaCl, 1% NP-40, 5 mM EDTA and pro-
tease/phosphatase inhibitor cocktail). Insoluble material was removed
by centrifugation. Proteins were resolved by SDS-PAGE and transferred
to polyvinylidene diﬂuoride membranes. Membranes were blocked
with 5% non-fat milk in phosphate-buffered saline and then probed
with the appropriate primary antibody in 5% non-fat milk overnight at
4 °C [AMPKα, phospho-AMPKα (Thr172), Bax, cleaved PARP, cleaved
caspase-3, Hexokinase 2, ATG5, ATG7, Beclin 1, ULK1, and LC3-II from
Cell Signaling; β Tubulin (G-8) and Bcl-2 (N-19) from Santa Cruz Bio-
technology; AR for IHC from Millipore and AR for Western blot from
Santa Cruz; and LC3 (M115–3) from MBL International Corporation].
Subsequently, membranes were washed in phosphate-buffered saline
with 0.3% Tween 20, and incubated with secondary antibody conjugat-
ed to horseradish peroxidase. Proteins were visualized by enhanced
chemiluminescence.
4.11. Immunohistochemistry (IHC)
All immunohistochemical analyses were conducted as previously
described (Wang et al., 2009). The following antibodies were used:
HK2, cleaved caspase-3, p-AMPK(Thr172), and LC3B (LC3II) from Cell
Signaling; Ki-67 from Thermo Scientiﬁc; AR from Millipore.
4.12. Plasmids and viral transfections
pQCXIP-GFP-LC3 was constructed by inserting GFP-LC3 into BamH1
and EcoRI restriction sites of pQCXIP vector and veriﬁed by DNA
sequencing. pcDNA-Bcl2 were generated using methods previously de-
scribed (Deng et al., 2003). All shRNAs were obtained from the
BioMedical Genomics Center at The University of Minnesota. These are
lentiviral shRNAs and are as follows: human PTEN (TRCN0000002747
and TRCN0000002749), human ULK1 (TRCN0000000835 and TRCN
0000000836), human AMPK (TRCN0000000857 and TRCN00
00000858), human Bax (TRCN0000033470 and TRCN0000033471),
HK2 (TRCN0000037670 and TRCN0000037673 for human; TRCN0
000012545 and TRCN0000012546 for mouse), human ATG5
(TRCN0000151963 and TRCN0000150645), human ATG7 (TRCN00
00007584 and TRCN0000007585), human Beclin1 (TRCN0000033549
and TRCN0000033552), and human p70SRK (TRCN0000022904 and
TRCN0000022907). The negative control vector was the pLKO.1 vector
backbones that has no hairpin insert. shRNA-encoding plasmids were
co-transfected with envelope and packaging plasmids (VSVG, REV and
pMDL) into actively growing HEK-293 T cells using the calciumphosphate transfection method. Virus-containing supernatants were
collected 36 h after transfection, centrifuged to remove cell debris and
ﬁltered to eliminate cells. The target cells were infected in the presence
of 8 μg/ml polybrene. Cells were selected with 8 μg/ml puromycin 24 h
later to generate stable cell lines and knockdown efﬁciency was con-
ﬁrmed by immunoblotting.
4.13. Statistical analyses
Statistical comparisons were analyzed by ANOVA (greater than two
groups) or Student's t test (two groups only) with Graphad Prism (v.5).
The difference in survival is determined by log-rank test. Data are
expressed as means ± SEM. Statistical signiﬁcances were accepted at
p b 0.05.
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